

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
28 August 2014 (28.08.2014)

(10) International Publication Number
WO 2014/127917 A8

- (51) International Patent Classification:
A61K 39/395 (2006.01) *A61K 39/39* (2006.01)
C07K 16/28 (2006.01)
- (21) International Application Number:
PCT/EP2014/000461
- (22) International Filing Date:
21 February 2014 (21.02.2014)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
PCT/EP2013/000526
22 February 2013 (22.02.2013) EP
- (71) Applicant: CUREVAC GMBH [DE/DE]; Paul-Ehrlich
Str. 15, 72076 Tübingen (DE).
- (72) Inventors: FOTIN-MLECZEK, Mariola; Chemnitzer
Weg 10, 71065 Sindelfingen (DE). KALLEN, Karl-Josef;
Marienhofer Weg 24, 50226 Königsdorf (DE). PROBST,
Jochen; In den Kirchhofländern 19, 72649 Wolfschlügen
(DE).
- (74) Agents: GRAF VON STOSCH, Andreas et al.; Graf von
Stosch, Patentanwalts-gesellschaft mbH, Prinzregenten-
strasse 22, 80538 München (DE).
- (81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))

(48) Date of publication of this corrected version:

4 December 2014

(15) Information about Corrections:

see Notice of 4 December 2014

Previous Correction:

see Notice of 30 October 2014

(54) Title: COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAY

(57) Abstract: The present invention relates to a vaccine/inhibitor combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one PD-1 pathway inhibitor, preferably directed against PD-1 receptor or its ligands PD-L1 and PD-L2. The present invention further relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/inhibitor combination. Additionally the present invention relates to medical use of such a vaccine/inhibitor combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/inhibitor combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with a PD-1 pathway inhibitor and to the use of a PD-1 pathway inhibitor in therapy in combination with an RNA vaccine.



WO 2014/127917 A8

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2014/127917 A8

(43) International Publication Date
28 August 2014 (28.08.2014)

- (51) International Patent Classification:
A61K 39/395 (2006.01) *A61K 39/39* (2006.01)
C07K 16/28 (2006.01)
- (21) International Application Number:
PCT/EP2014/000461
- (22) International Filing Date:
21 February 2014 (21.02.2014)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
PCT/EP2013/000526
22 February 2013 (22.02.2013) EP
- (71) Applicant: CUREVAC GMBH [DE/DE]; Paul-Ehrlich
Str. 15, 72076 Tübingen (DE).
- (72) Inventors: FOTIN-MLECZEK, Mariola; Chemnitzer
Weg 10, 71065 Sindelfingen (DE). KALLEN, Karl-Josef;
Marienhofer Weg 24, 50226 Königsdorf (DE). PROBST,
Jochen; In den Kirchholfländern 19, 72649 Wolfschlügen
(DE).
- (74) Agents: GRAF VON STOSCH, Andreas et al.; Graf von
Stosch, Patentanwalts-gesellschaft mbH, Prinzregenten-
strasse 22, 80538 München (DE).
- (81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))

(48) Date of publication of this corrected version:

30 October 2014

(15) Information about Correction:

see Notice of 30 October 2014

(54) Title: COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAY

(57) Abstract: The present invention relates to a vaccine/inhibitor combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one PD-1 pathway inhibitor, preferably directed against PD-1 receptor or its ligands PD-L1 and PD-L2. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/inhibitor combination. Additionally the present invention relates to medical use of such a vaccine/inhibitor combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/inhibitor combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with a PD-1 pathway inhibitor and to the use of a PD-1 pathway inhibitor in therapy in combination with an RNA vaccine.



WO 2014/127917 A8